“Norwegian Ultimovacs continues to expand its clinical development pipeline with universal cancer vaccine UV1. This week, the company announced its plan to initiate a fifth phase II trial with the candidate – a combination study with checkpoint inhibitor pembrolizumab in non-small cell lung cancer. The study will be conducted at 8-10 sites across Norway and led by principal investigator Professor Odd Terje Brustugun.”
Read the full article here